Synthetic Biology-Based Therapeutics Summit

Investigate Foundational Technologies, Applications, and Manufacturing Strategies to Create Advanced, Controllable Drugs at the Only Technical Meeting to Explore the Therapeutic Applications of Synthetic Biology.

This year, the synthetic biology market has seen fledgling companies rise to IPO smashing power players, as the demand for high-quality, engineered biomolecules and controllable therapeutics grows exponentially. The therapeutic potential of novel synthetic units is huge, but challenges remain in demonstrating proof-of-concept, developing assays, functional characterization, manufacturing scale-up, and identifying therapeutic applications for commercial development.

With an agenda curated by leaders in synthetic biology-based therapies at Synlogic, Merck, Bayer, Senti Bio, MIT and GSK, the Synthetic Biology-Based Therapeutics Summit will provide strategic insights to deploy synthetic biology as a tool for discovery, through to therapeutic applications.

Explore innovations in circuit design and implementation, harnessing the power of computation and AI to better design functioning circuits and uncover novel components which elicit therapeutic benefit. Tackle manufacturing challenges to scale up synthetic biology-based therapeutics with gold-standard quality control and characterization.

Prices:

Industry Pricing - Pharma and Biotech - Conference + 2 Workshops: USD 2897.00,
Industry Pricing - Pharma and Biotech - Conference + 1 Workshop: USD 2498.00,
Industry Pricing - Pharma and Biotech - Conference Only: USD 2099.00,
Academic and Start-Up Pricing - Conferences + 2 Workshops: USD 2497.00,
Academic and Start-Up Pricing - Conference + 1 Workshop: USD 2198.00,
Academic and Start-Up Pricing - Conference Only: USD 1899.00,
Standard Service Provider Pricing - Conferences + 2 Workshops: USD 3597.00,
Standard Service Provider Pricing - Conferences + 1 Workshop: USD 3098.00,
Standard Service Provider Pricing - Conferences Only: USD 2599.00

URLs:

Tickets: https://go.evvnt.com/853527-2?pid=5248

Brochure: https://go.evvnt.com/853527-3?pid=5248

Speakers: Aaron Cooper, Director Synthetic Biology, ArsenalBio, Jak Knowles, CEO, Affini-T Therapeutics, Sheila Mikhail, CEO, AskBio, Naveen Krishnan, Senior Director Venture Investments Health, Leaps by Bayer, Lee Cooper, Senior Director Venture Investments Health, Leaps by Bayer, Raja Srinivas, Founder, Asimov, Edward Green, Founder and CEO, CHAIN Biotech, Eric Kelsic, Founder and CEO, Dyno Therapeutics, J. Casey Lippmeier, VP, Innovation, Conagen, Mark Kotter, Founder and CEO, bit.bio, Paul Feldstein, CSO and Co-Founder, Circularis Biotechnology, Wenning Qin, VP Genome Engineering, eGenesis, Andrew Phillips, Head of Synthetic Biology, Microsoft, Francesco Marincola, Global Head of Research, Kite: A Gilead Company, Grant Murphy, Director Protein Engineering, Merck, Janice Chen, Co-Founder and CTO, Mammoth Biosciences, Qi Cai, Director Cell Biology, Kite: A Gilead Company, Xavier Duportet, Co-founder and CEO, Eligo Bioscience, James Collins, Termeer Professor of Medical Engineering and Science, Broad Institute of MIT and Harvard, Ron Weiss, Professor of Biological Engineering, MIT, William DeLoache, CSO and Co-Founder, Novome Biotechnologies, David Hava, CSO, SynLogic, Maria Soloveychik, Founder and CEO, Synthex, Tasuku Kitada, Co-Founder, Director, President, Head of R&D, Strand Therapeutics, Timothy Lu, CEO, Senti Biosciences

Sesh by The Boston Calendar | Advertise Terms | Privacy Policy | About